长期体重管理药物减重版司美格鲁肽获批心血管适应症

Core Insights - Novo Nordisk announced that its weight-loss drug semaglutide injection (brand name: Ozempic) has received approval from the National Medical Products Administration (NMPA) in China for cardiovascular indications, marking it as the first GLP-1 weight-loss drug approved for cardiovascular indications in the country [1] Group 1 - The approved indication is aimed at reducing the risk of major cardiovascular adverse events in adults diagnosed with cardiovascular disease and a BMI of ≥27 kg/m² [1]